Clinical Evaluation

Glucosa Factor (capsules):

A clinical evaluation of the efficacy and safety of a combination of Ayurvedics, Benzylisoquinoline alkaloids and organosulfur compounds in the preventing and onset of type 2 diabetes, glycemic control and repair of pancreatic damage for patients with type 2-diabetes.

SETTINGS/LOCATION:
This study was conducted in two major peripheral clinics of Kuala Lumpur in the Klang Valley, Malaysia.

39 cases treated with Glucosa Factor formula

A total of 39 treated cases and 40 age-matched controls were recruited for this preliminary study. Nineteen (19) subjects (10 and 9 from control and treatment groups, respectively) dropped out of the study leaving a total of 60 subjects (30 each for control and treatment groups) who completed the study.

All subjects in the treatment group were given the Glucosa Factor formula (One (1) capsule twice daily after meals) in addition to the regular allopathic drugs (Daonil, [Aventis Farma, SA Petaling Jaya, Selangor State, Malaysia] and Diamicron [Sevier, Bangkok, Thailand], with or without Metformin [Upohn Corporation, Bangi, Selangor State, India]) that they took in common with the control group.

OUTCOME MEASURES:

Thirty-two (32) clinical variables were investigated

Thirty-two (32) clinical variables were investigated, including liver enzymes, kidney function tests, hematologic parameters, blood glucose, insulin, and C-peptide assays.that they took in common with the control group

All subjects in the treatment group were given the Glucosa Factor formula (One (1) capsule twice daily after meals) in addition to the regular allopathic drugs (Daonil, [Aventis Farma, SA Petaling Jaya, Selangor State, Malaysia] and Diamicron [Sevier, Bangkok, Thailand], with or without Metformin [Upohn Corporation, Bangi, Selangor State, India]) that they took in common with the control group.

RESULTS

Significant decrease in Glucose levels and more

At the end of 3 months it was found that there was a significant decrease in the levels of fasting and postprandial blood glucose, cholesterol, triglycerides, glycated hemoglobin (Hb A(1C)) and fasting insulin in the treatment group compared to the controls. The formula did not alter the liver function tests, hematologic parameters, or the kidney function tests.

CONCLUSIONS

The formula is safe, reliable, tolerable, and efficacious

At the end of 3 months it was found that there was a significant decrease in the levels of fasting and postprandial blood glucose, cholesterol, triglycerides, glycated hemoglobin (Hb A(1C)) and fasting insulin in the treatment group compared to the controls. The formula did not alter the liver function tests, hematologic parameters, or the kidney function tests.

Over 86 Miliion Americans have prediabetes
Prediabetes can be reversed, Know where you stand.